HER2 in Uterine Serous Carcinoma: Testing platforms and implications for targeted therapy


Tenley Klc, Sharon Wu, Annelise M Wilhite, Nathaniel L. Jones, Matthew A. Powell, Alexander Olawaiye, Fiona Simpkins, Eugenia Girda, Jubilee Brown, Allison Puechl, Rouba Ali-Fehmi, Ira Seth Winer, Thomas J Herzog, Wolfgang Michael Korn, Britt Kristina Erickson

Background: HER2 is an emerging prognostic and therapeutic target in uterine serous carcinoma (USC). Testing algorithms and platforms in breast and gastric cancers are well studied and validated, but optimal HER2 testing in uterine cancer is not yet established. We aimed to assess the concordance of chromogenic in situ hybridization (CISH), immunohistochemistry (IHC), and next generation sequencing (NGS) platforms to aid in the development of USC specific testing guidelines. We also evaluated the rate of downstream mutations that may affect response to HER2 directed therapy.

Download Publication